Biocept Inc (BIOCQ) USD0.0001

Sell:$0.00Buy:$0.00No change

Prices delayed by at least 15 minutes
Sell:$0.00
Buy:$0.00
Change:No change
Prices delayed by at least 15 minutes
Sell:$0.00
Buy:$0.00
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

Biocept, Inc. is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. The Company has developed a patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). As such, it is a commercial provider of testing services designed to enable clinicians to rapidly detect and monitor cancer biomarkers from a cerebrospinal fluid sample. The Company operates a clinical laboratory and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. The assays the Company offers are classified as laboratory developed tests (LDT) under the CLIA regulations. The Company’s assays, performed on cerebral spinal fluid, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease.

Key people

Philippe J. Marchand
Chief Operating Officer
Robert Walsh
Principal Accounting Officer, Vice President, Controller
Darrell Taylor
Chief Legal Officer and Chief Compliance Officer
Nathaniel Sweed
Medical Director
Bruce E. Gerhardt
Independent Chairman of the Board
M. Faye Wilson
Lead Independent Director
Marsha A. Chandler
Independent Director
Click to see more

Key facts

  • EPIC
    BIOCQ
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US09072V6002
  • Market cap
    $260.00
  • Employees
    50
  • Shares in issue
    2.63m
  • Exchange
    Over The Counter
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.